Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.
[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)]
7992332
{7992332:BBBBBBBB}
apa
50
1
170518
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/